In our case-control analyses with a non-cancer east-Asian population and non-cancer females, we found significant prevalence of PALB2, BARD1, BLM, and ATM mutations in our HBOC cohort, including patients with ovarian cancer. Here, BARD1 is linked to ovarian carcinoma.